Myriad Genetics To Present MyRisk Data At Seattle Conference
Zacks Investment Research | Sep 28, 2016 05:53AM ET
Molecular diagnostics and personalized medicine major, Myriad Genetics, Inc. (NASDAQ:MYGN) is gearing up to present three new myRisk Hereditary Cancer studies with favorable data at the National Society of Genetic Counselors Annual Education Conference, beginning today through Oct 1, 2016, at Seattle, WA.
All three studies, namely Average Age of Diagnosis of Ovarian Cancer for Women with Pathogenic Variants in BRIP1, RAD51C and RAD51D; Ancestry-Based Cancer Risks Associated with APC I1307K and Psychosocial Outcomes of Identifying High or Moderate Risk Mutation Carriers by Hereditary Cancer Panel Testing will demonstrate the benefits of gene panel testing, which will thereby improve the practice of genetic counseling.
Development with myRisk So Far
Myriad’s major product, myRisk Hereditary Cancer test that was launched in 2013, has a market opportunity of more than $5 billion. In 2014, Myriad initiated the domestic launch of this test, with an aim to transform the entire hereditary cancer market toward myRisk by discontinuing its legacy flagship product – the BRACAnalysis test. During fourth-quarter fiscal 2016, Myriad successfully completed the conversion to myRisk among its targeted physicians and made gene panel the standard of care within the marketplace.
MYRIAD GENETICS Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.